PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday.
Omnicare CR, headquartered in King of Prussia, Pa., conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services.
As part of the deal, its parent company, Ominicare Inc., has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years.
“Omnicare has carved out an attractive niche in the [clinical research organization] industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market,” said Chris Crosby, managing director of Nautic. The firm did not disclose the financial details of the acquisition.
It is the 10th investment by Nautic Partners’ most recent fund, Nautic Partners VI, and its third health care investment.